Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NAPROSYN AND ANAPROX FIRST QUARTER SALES HIT $137 MIL., AS NSAIDS MAKE UP TWO-THIRDS OF SYNTEX DRUG VOLUME; MEDICINE SHOPPE FISCAL 1986 PROFITS UP

Executive Summary

Worldwide sales of Naprosyn (naproxen) and Anaprox (naproxen sodium) increased 7% to $137.3 mil. during the first quarter, Syntex reported. Together the two NSAIDs made up 65% of the company's $211.5 mil. total pharmaceutical sales and over half of its $263 mil. corporate volume. Much of the increase took place outside the U.S, however, where combined sales of Naprosyn and Anaprox jumped 20% to $43 mil. Sales in the larger U.S. market increased only 2% to $94 mil. The company attributed the sales growth outside the U.S. to a weakening dollar and higher volume. For the three months ended Oct. 31, Syntex reported a 31% increase in net earnings, from $49 mil. in the first quarter of fiscal 1986 to $64 mil. "Our record earnings performance was made possible by increased pharmaceutical sales; good growth in our diagnostics business; and improved performance in our animal health business," Syntex Chairman Albert Bowers, PhD, noted. The earnings jump came on a 7% increase in total corporate sales. Syntex also reported that R&D spending was approximately 11% higher than in the same quarter of fiscal 1986. The company said that for all of fiscal 1987 it plans to increase R&D spending roughly 20%. Medicine Shoppe showed strong sales and earnings growth for both the quarter and year ended Sept. 30. Three-month volume was up nearly 27% to $4.7 mil., while net earnings made a similar move, rising 26% to just over $1 mil. For all of fiscal 1986, volume and profits increased in excess of 20%. Year-end sales were up 22.3% to nearly $17 mil. and net earnings jumped almost 21% to $3.6 mil. Chart omitted.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS011122

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel